|
|
 |
|
Viewing report
|
|
|
|
Bristol-Myers Squibb Co.: PharmaVitae Profile
Datamonitor, March 2011, Pages: 84
This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Bristol-Myers Squibb's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
- Strategic insight into the prospects for BMS over the next six years.
- Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark BMS's performance against key rivals in the prescription pharmaceutical sector
- Determine the value of BMS's piepline and other strategies the company is taking to counteract an imminent wave of generic compeitition.
- Assess what makes BMS a model biopharma company and why its newfound focus could lead to the industry's next megamerger
|
|
|
|
